TRACON's late-stage study underway assessing lead product candidate TRC105 in angiosarcoma

• The first patient has been dosed in TRACON Pharmaceuticals' (NASDAQ:TCON) Phase 3 clinical trial, TAPPAS, evaluating lead product candidate TRC105 for the treatment of angiosarcoma, a cancer of the inner lining of blood vessels.
• The 124-subject study will assess the combination of TRC105 and Novartis' (NVS) Votrient (pazopanib) versus Votrient alone. The primary endpoint is progression-free survival at month 24. According to ClinicalTrials.gov, the estimated study completion date is December 2018.
• TRC105 (carotuximab) is a novel clinical-stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis. It has Orphan Drug status for the treatment of soft tissue sarcoma and Fast Track status for kidney cancer.
• Previously: TRACON Pharma clarifies development path for lead product candidate; shares ahead 11% (Jan. 3)